HC Wainwright Reiterates “Buy” Rating for Aligos Therapeutics (NASDAQ:ALGS)

HC Wainwright reaffirmed their buy rating on shares of Aligos Therapeutics (NASDAQ:ALGS) in a research report released on Wednesday morning, Benzinga reports. HC Wainwright currently has a $75.00 price objective on the stock.

Aligos Therapeutics Stock Down 7.0 %

ALGS opened at $8.40 on Wednesday. The firm has a market cap of $656.12 million, a PE ratio of -6.56 and a beta of 2.16. The business has a fifty day simple moving average of $10.59 and a 200-day simple moving average of $13.53. Aligos Therapeutics has a fifty-two week low of $6.76 and a fifty-two week high of $30.00.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.75 earnings per share for the quarter, topping the consensus estimate of ($4.00) by $4.75. The business had revenue of $1.06 million during the quarter. Aligos Therapeutics had a negative return on equity of 110.59% and a negative net margin of 1,100.48%. During the same period in the prior year, the business earned ($10.75) earnings per share. On average, equities research analysts anticipate that Aligos Therapeutics will post -8.2 EPS for the current fiscal year.

Institutional Trading of Aligos Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of ALGS. Armistice Capital LLC boosted its position in shares of Aligos Therapeutics by 5.3% in the second quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock worth $2,540,000 after buying an additional 363,000 shares during the period. Opaleye Management Inc. boosted its position in shares of Aligos Therapeutics by 25.7% in the first quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock worth $1,597,000 after buying an additional 333,000 shares during the period. Finally, Acadian Asset Management LLC boosted its position in shares of Aligos Therapeutics by 26.1% in the second quarter. Acadian Asset Management LLC now owns 829,485 shares of the company’s stock worth $289,000 after buying an additional 171,490 shares during the period. Institutional investors and hedge funds own 60.43% of the company’s stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).